Ohtsu A, Shimada Y, Shirao K, et al: Randomized phase III trial of fluorouracil alone versus fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin in patients with unresectable, advanced gastric cancer: The Japan Clinical Oncology Group Study (JCOG 9205). J Clin Oncol 21(1): 54-59, 2003.
Grothey A, Sargent D, Goldberg RM, et al: Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol 22(7): 1209-1214, 2004.
Moiseyenko VM, Ajani JA, Tjulandin SA, et al: Final results of a randomized controlled phase III trial (TAX 325) comparing docetaxel (T) combined with cisplatin (C) and 5-fluorouracil (F) to CF in patients (pts) with metastatic gastric adenocarcinoma (MGC) Proc ASCO (abstr 4002), 2005.
Wagner AD, Grothe W, Haerting J, et al: Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. J Clin Oncol 24(18): 2903-2909, 2006.
Dank M, Zaluski J, Barone C, et al: Randomized phase 3 trial of irinotecan (CPT-11) + 5 FU/folinic acid (FA) vs CDDP+ 5 FU in 1 st-line advanced gastric cancer patients. Proc ASCO (abstr 4003), 2005.